May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Transscleral Permeability of Fluorescent–Labeled Antibiotics
Author Affiliations & Notes
  • J.C. Kao
    Ophthalmology, Emory University, Atlanta, GA
  • D.H. Geroski
    Ophthalmology, Emory University, Atlanta, GA
  • H.F. Edelhauser
    Ophthalmology, Emory University, Atlanta, GA
  • Footnotes
    Commercial Relationships  J.C. Kao, None; D.H. Geroski, None; H.F. Edelhauser, None.
  • Footnotes
    Support  NEI Grant P30 EY06360, FFB, and RPB
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 5044. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.C. Kao, D.H. Geroski, H.F. Edelhauser; Transscleral Permeability of Fluorescent–Labeled Antibiotics . Invest. Ophthalmol. Vis. Sci. 2004;45(13):5044.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the in vitro transscleral permeability of antibiotics for posterior segment infection. Methods: Superior temporal sections of sclera were excised from moist–chamber human globes and mounted in a two–compartment perfusion chamber. Antibiotics (either fluorescent–labeled vancomycin, polymyxin B, or penicillin) were added to the donor hemichamber above the episcleral surface, while the receiver hemichamber below the choroidal surface was slowly perfused with BSS. A fraction collector was used to collect samples from the receiver chamber every hour, for a total of 24 hours. Concentration was measured using a fluorometer. From this data, the transscleral permeability (Ktrans, cm/sec) was calculated. Results: Ktrans for the transscleral diffusion of vancomycin (MW 1723.35 g/mol, n=12) was 1.46 ± 0.42 x 10–7 cm/s (mean +/– SEM). After a 24–hour experiment, 4.4 ± 1.2% of the total vancomycin diffused across the sclera, while 23.3 ± 2.4% remained in the scleral tissue and 19.3 ± 3.8% remained in the donor chamber. Ktrans for polymyxin B (MW 1800 g/mol, n=9) was 3.80 +/– 0.61 x 10–7 cm/s. After 24 hours, 17.2 ± 1.7% of the total polymyxin B diffused across the sclera, while 11.2 ± 1.8% remained in the scleral tissue and 14.2 ± 3.8% remained in the donor chamber. Ktrans for penicillin (MW 661.46 g/mol, n=10) was 2.10 +/– 0.41 x 10–6 cm/s. After 24 hours, 63.6 ± 10.2% of the total penicillin diffused across the sclera. Conclusions: Human sclera has been shown in previous studies to be permeable to a variety of compounds with different molecular weights. This study shows that, with respect to antibiotics, human sclera is more permeable to lower molecular–weight penicillin than to vancomycin or polymyxin B. In all cases, though, measurable concentrations of drug could be detected across the sclera. This series of experiments suggests that a local, non–invasive transscleral drug delivery method is feasible for using antibiotics to treat intraocular infections. These results also infer that other drugs can be applied transsclerally to treat a variety of diseases in the posterior segment.

Keywords: sclera • pharmacology • antibiotics/antifungals/antiparasitics 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×